

AI-Assisted Rare Disease Diagnosis: Integrating Genomic Evidence and Clinical Intelligence

Tauhid Zaman

Lecturer Yale University

Abstract

Rare diseases present major diagnostic challenges because of their low individual prevalence, substantial genetic heterogeneity, overlapping clinical manifestations and limited availability of disease-specific expertise. Patients may experience prolonged diagnostic journeys involving repeated consultations, inconclusive investigations and inappropriate or delayed treatment. Advances in artificial intelligence (AI), genomic sequencing and clinical informatics are creating new opportunities to improve rare disease diagnosis by integrating molecular evidence with phenotypic and clinical information. This paper examines the emerging role of AI-assisted diagnostic systems that combine genomic variants, electronic health records, clinical phenotypes, medical imaging, laboratory findings and biomedical knowledge. It proposes an Integrated Genomic-Clinical Intelligence Framework comprising five major components: multimodal clinical data acquisition, genomic variant interpretation, phenotype representation, AI-based evidence integration and clinician-guided diagnostic decision support. Applications of machine learning, deep learning, natural language processing, knowledge graphs and large language models in rare disease diagnosis are discussed. Particular attention is given to variant prioritisation, phenotype-driven gene discovery, genotype-phenotype matching and differential diagnosis. The paper also examines challenges related to incomplete genomic penetrance, variant interpretation, data quality, population diversity, explainability, privacy, algorithmic bias and clinical validation. The analysis suggests that AI should function primarily as an evidence-integration and decision-support technology rather than an autonomous diagnostic authority. Future rare disease diagnosis will increasingly depend on interoperable genomic and clinical datasets, multimodal AI models, continuously updated knowledge bases and human-AI collaboration. The paper concludes that responsible integration of genomic evidence and clinical intelligence could shorten diagnostic journeys, improve diagnostic accuracy and facilitate earlier personalised management for patients with rare diseases.

Keywords: Artificial Intelligence, Rare Diseases, Genomic Medicine, Clinical Intelligence, Machine Learning, Variant Interpretation, Phenotype Analysis, Precision Medicine, Clinical Decision Support, Genotype-Phenotype Integration.

1. Introduction

Rare diseases collectively affect a substantial global population despite the low prevalence of individual conditions.

Many rare diseases are genetic in origin, creating a strong connection between:

Clinical Presentation ↔ Genomic Variation ↔ Disease Mechanism

However, identifying the disease-causing variant is often difficult.

A patient may present with:

- Multiple nonspecific symptoms.
- Atypical disease manifestations.
- Several affected organ systems.
- Variable disease progression.
- An uncommon combination of clinical features.

Consequently, conventional diagnostic pathways can require substantial time and specialist expertise.

Artificial intelligence provides an opportunity to integrate large quantities of heterogeneous clinical and genomic information.

The emerging diagnostic model can therefore be represented as:

Clinical Data + Phenotypic Evidence + Genomic Data + Biomedical Knowledge → AI-Assisted Diagnostic Reasoning

2. Understanding Rare Diseases

Rare diseases represent a diverse group of disorders involving:

- Genetic abnormalities.
- Metabolic dysfunction.
- Immune-system abnormalities.
- Neurological disorders.
- Developmental conditions.
- Rare cancers.

Many are individually uncommon but collectively represent a major healthcare challenge.

3. The Diagnostic Challenge

Rare disease diagnosis is difficult because of several factors.

Major challenges include:

1. Low disease prevalence.

2. Clinical heterogeneity.
3. Genetic heterogeneity.
4. Incomplete penetrance.
5. Variable expressivity.
6. Limited clinical expertise.
7. Incomplete disease databases.
8. Uncertain genetic variants.

These factors create a complex diagnostic environment.

4. The Diagnostic Odyssey

Many rare-disease patients experience a prolonged period between initial symptoms and definitive diagnosis.

This process is sometimes described as the diagnostic odyssey.

It may involve:

Symptoms → Primary Care → Multiple Specialists → Repeated Tests → Genetic Testing → Reanalysis → Diagnosis

AI-assisted systems could potentially shorten this pathway by identifying meaningful relationships earlier.

5. Genomic Medicine

Genomic sequencing provides detailed information about an individual's DNA.

Major approaches include:

- Whole-genome sequencing.
- Whole-exome sequencing.
- Targeted sequencing.
- RNA sequencing.

These technologies can identify genetic variants that may contribute to disease.

6. Variant Interpretation

Identifying a genetic variant is not equivalent to identifying the disease.

A sequencing analysis may produce:

Thousands of Genetic Variants



Variant Filtering



Candidate Variants



Clinical Interpretation



Potential Disease Diagnosis

AI can assist in prioritising variants based on multiple evidence sources.

7. Clinical Phenotypes

Phenotype refers to observable characteristics associated with a patient.

Examples include:

- Developmental delay.
- Seizures.
- Abnormal muscle tone.
- Cardiac abnormalities.
- Vision impairment.
- Growth abnormalities.
- Metabolic disturbances.

Representing these features computationally enables AI systems to compare patients with known disease phenotypes.

8. Genotype-Phenotype Integration

The central principle of AI-assisted rare disease diagnosis is the integration of:

Genotype

With

Phenotype

A candidate gene becomes more compelling when:

- The genetic evidence is strong.
- The patient's phenotype is compatible.
- Biological mechanisms are plausible.
- Previous disease associations exist.

9. Artificial Intelligence in Rare Disease Diagnosis

AI can support multiple stages of the diagnostic workflow.

Potential applications include:

- Phenotype extraction.
- Variant prioritisation.
- Gene ranking.
- Differential diagnosis.
- Medical-image analysis.
- Clinical-document analysis.
- Literature analysis.

10. Machine Learning

Machine-learning systems can identify patterns within large datasets.

For rare diseases, models can learn relationships between:

Genetic Variants + Phenotypes + Diseases

This can support ranking of candidate diagnoses.

11. Deep Learning

Deep-learning models can process complex data such as:

- Genomic sequences.
- Medical images.
- Clinical notes.
- Protein structures.

Their ability to identify nonlinear relationships may be useful in complex diagnostic problems.

12. Natural Language Processing

Clinical records frequently contain important information in unstructured text.

NLP can extract:

- Symptoms.
- Diagnoses.
- Family history.
- Laboratory findings.
- Disease progression.
- Medication history.

This information can then be incorporated into diagnostic models.

13. Phenotype Extraction

A patient's clinical narrative might state:

"The child developed seizures during infancy and subsequently showed progressive developmental delay."

An NLP system can transform this narrative into structured clinical features.


This creates:

Clinical Narrative → Structured Phenotypes → Computational Analysis

14. Phenotype Similarity

AI systems can compare a patient's phenotype with known disease profiles.

A conceptual workflow is:



This can help prioritise diagnostic possibilities.

15. Knowledge Graphs

Knowledge graphs represent relationships between biomedical entities.

For example:

Gene → Protein → Biological Pathway → Phenotype → Disease

AI can use these relationships to identify connections that may not be immediately obvious to clinicians.

16. Genomic Knowledge Graphs

A genomic knowledge graph may integrate:

- Genes.
- Variants.
- Diseases.
- Phenotypes.
- Proteins.
- Pathways.
- Publications.

This creates a structured representation of biomedical knowledge.

17. Variant Prioritisation

Variant prioritisation is one of the most important applications.

An AI system can rank variants according to:

- Population frequency.
- Predicted functional impact.
- Inheritance pattern.
- Phenotype compatibility.
- Existing disease evidence.
- Gene-disease relationships.

18. Family-Based Genomic Analysis

When parental genomic information is available, AI can analyse inheritance patterns. For example:

Child + Mother + Father

may allow identification of:

- De novo variants.
- Recessive inheritance.
- Compound heterozygosity.
- X-linked inheritance.

19. De Novo Variant Detection

Some genetic disorders result from variants that are not inherited from either parent. AI can assist in prioritising de novo variants by integrating:

- Sequencing evidence.
- Variant quality.
- Gene function.
- Phenotype compatibility.

20. Incomplete Penetrance

Not every person carrying a disease-associated variant necessarily develops the same phenotype.

AI models must therefore account for:

- Penetrance.
- Age.
- Environmental factors.
- Modifier genes.

This makes diagnostic reasoning more complex.

21. Variable Expressivity

Individuals with variants in the same gene may have different clinical manifestations. Therefore:

Same Gene ≠ Identical Clinical Presentation

AI models must accommodate phenotypic variability.

22. Multimodal AI

Future diagnostic systems may integrate:

- Genomic sequences.
- Clinical notes.

- Laboratory data.
- Medical images.
- Family history.
- Patient-reported information.

This creates a multimodal diagnostic intelligence system.

23. Medical Imaging

Some rare diseases have characteristic imaging patterns.

AI can analyse:

- MRI.
- CT.
- Ultrasound.
- Radiographs.
- Ophthalmic images.

Imaging evidence can be combined with genomic and clinical information.

24. Laboratory Data

Laboratory abnormalities may provide important clues.

Potential inputs include:

- Blood chemistry.
- Hormone levels.
- Metabolic profiles.
- Enzyme activity.
- Haematological parameters.

AI can identify combinations that may indicate specific disorders.

25. Multi-Omics Integration

Beyond DNA sequencing, diagnostic systems can potentially incorporate:

- Transcriptomics.
- Proteomics.
- Metabolomics.
- Epigenomics.

This enables:

Genome → Gene Expression → Protein → Metabolism → Phenotype
analysis.

26. AI and Functional Genomics

When a genetic variant has uncertain clinical significance, functional evidence can be valuable.

AI can integrate information about:

- Gene expression.
- Protein function.
- Cellular pathways.
- Tissue specificity.

This can improve variant interpretation.

27. Large Language Models

Large language models may assist clinicians by processing large quantities of biomedical information.

Potential applications include:


- Summarising clinical histories.
- Extracting phenotypes.
- Searching biomedical literature.
- Generating differential diagnoses.
- Explaining genomic evidence.

However, outputs require clinical verification.

28. Retrieval-Augmented Diagnostic Systems

A safer architecture may combine AI generation with verified biomedical databases.

The process can be:



This can reduce unsupported AI-generated claims.

29. Explainable AI

Clinical decision support requires transparency.

An AI system should ideally explain:

- Which phenotype contributed to the prediction.
- Which variant was prioritised.

- What evidence supports the gene-disease relationship.
- What uncertainties remain.

30. Evidence-Based Diagnostic Ranking

Instead of producing only:

Diagnosis: Disease X

a more useful system could provide:

Rank	Candidate	Supporting Evidence	Uncertainty
1	Disease A	Strong genomic + phenotypic match	Moderate
2	Disease B	Strong phenotype	High
3	Disease C	Partial genetic evidence	High

This better supports clinical decision-making.

31. Clinical Decision Support


AI should primarily function as a clinical decision-support tool.

The physician remains responsible for:

- Clinical interpretation.
- Patient communication.
- Confirmatory testing.
- Treatment decisions.

32. Human-AI Collaboration

An effective workflow can be represented as:



33. Proposed Integrated Genomic-Clinical Intelligence Framework

The proposed framework contains six layers.

Layer 1 — Clinical Data

- Symptoms.
- Medical history.
- Family history.
- Laboratory findings.
- Imaging.

Layer 2 — Genomic Data

- DNA variants.
- Structural variants.
- Copy-number variants.
- Sequencing information.

Layer 3 — Knowledge Integration

- Gene-disease databases.
- Phenotype ontologies.
- Biomedical literature.

Layer 4 — AI Analytics

- NLP.
- Machine learning.
- Deep learning.
- Knowledge graphs.

Layer 5 — Diagnostic Ranking


Candidate genes and diseases are ranked according to integrated evidence.

Layer 6 — Clinical Validation

A healthcare professional evaluates the AI-generated evidence.

34. Diagnostic Workflow

A complete AI-assisted workflow could be:



35. Data Quality

AI performance depends heavily on data quality.

Potential problems include:

- Missing clinical information.
- Incorrect phenotype coding.
- Incomplete family histories.
- Sequencing errors.
- Inconsistent terminology.

High-quality data infrastructure is therefore essential.

36. Population Diversity

Genomic databases may contain unequal representation of populations.

This can create biases in variant interpretation.

A variant that appears rare in one population may be more common in another.

AI systems should therefore incorporate diverse genomic datasets.

37. Algorithmic Bias

AI models can inherit biases from their training datasets.

Bias can occur in:

- Patient populations.

- Disease representation.
 - Genomic databases.
 - Clinical documentation.
- Continuous evaluation is necessary.

38. Privacy

Genomic information is highly sensitive.
AI-based genomic systems must protect:

- Patient identity.
- Genetic information.
- Family information.
- Clinical records.

Security should be incorporated into system design.

39. Data Interoperability

Different healthcare systems use different:

- Data formats.
- Coding systems.
- Clinical terminology.

Interoperability is therefore critical.

Potential standards include structured representations for:

- Phenotypes.
- Genomic variants.
- Clinical observations.

40. Clinical Validation

An AI system should undergo rigorous evaluation before clinical deployment.

Evaluation should examine:

- Diagnostic accuracy.
- Sensitivity.
- Specificity.
- False-positive rates.
- False-negative rates.
- Calibration.
- Generalisability.

41. False Positives

An AI system may identify a gene or disease that appears plausible but is not actually responsible for the patient's condition.

This can lead to:

- Unnecessary testing.
- Anxiety.
- Misdiagnosis.

Human validation is therefore essential.

42. False Negatives

Failure to identify the correct diagnosis may delay treatment.

This is particularly concerning in rare diseases because patients may already have experienced prolonged diagnostic uncertainty.

43. Clinical Utility

Accuracy alone is insufficient.

A system should also demonstrate whether it:

- Reduces diagnostic time.
- Reduces unnecessary testing.
- Improves diagnostic yield.
- Improves clinician confidence.
- Improves patient outcomes.

44. Economic Implications

Earlier diagnosis can potentially reduce:

- Repeated consultations.
- Unnecessary diagnostic procedures.
- Ineffective treatments.
- Hospital utilisation.

However, AI infrastructure and genomic testing also introduce costs.

Economic evaluation is therefore required.

45. Ethical Considerations

Important ethical questions include:

- Who is responsible for an AI-supported diagnosis?
- How should uncertain findings be communicated?
- Should incidental genomic findings be disclosed?
- How should family members be informed?
- How should genomic data be stored?

46. Incidental Findings

Genomic sequencing may identify variants unrelated to the original diagnostic question.

Clinical systems need policies for:

- Reporting.

- Confirming.
- Communicating.
- Managing incidental findings.

47. Genetic Counselling

AI should complement rather than replace genetic counselling.

Patients may need professional guidance regarding:

- Inheritance.
- Family risk.
- Prognosis.
- Testing options.
- Psychological implications.

48. Rare Disease Registries

AI can benefit from high-quality rare disease registries.

Registries can provide:

- Longitudinal patient information.
- Phenotypic diversity.
- Genomic evidence.
- Treatment outcomes.

49. Federated Learning

Federated learning offers a potential approach for collaborative AI development.

Instead of moving sensitive patient data to a central location:

Hospital A

↘

Shared AI Model

↗

Hospital B

The underlying patient datasets can remain within participating institutions, subject to appropriate technical and governance safeguards.

50. Continuous Learning

Rare disease knowledge changes continuously.

New discoveries may identify:

- New disease genes.
- New variants.
- New genotype-phenotype relationships.
- New disease mechanisms.

AI systems therefore require mechanisms for controlled knowledge updating.

51. Diagnostic Knowledge Graph

A future diagnostic knowledge graph could connect:

Patient

- Phenotype
- Gene
- Variant
- Protein
- Pathway
- Disease
- Treatment

This provides a comprehensive evidence structure.

52. Precision Medicine

AI-assisted rare disease diagnosis supports precision medicine by connecting an individual's biological information to clinical decisions.

The broader model is:

Right Diagnosis → Right Patient → Right Intervention → Right Time

53. AI-Enabled Diagnostic Ecosystem

The future ecosystem may integrate:

Electronic Health Records

•

Genomic Sequencing

•

Imaging

•

Laboratory Data

•

Biomedical Literature

•

AI

↓

Clinical Intelligence

54. Proposed AI-Assisted Diagnostic Scoring Model

A conceptual diagnostic score could integrate:

Diagnostic Score = Genomic Evidence + Phenotypic Similarity + Clinical Evidence +
Biological Evidence – Uncertainty

The precise mathematical weighting would require clinical validation and disease-specific calibration.

55. Research Questions

1. How accurately can AI integrate genomic and phenotypic evidence?
2. Can AI reduce the duration of rare disease diagnostic journeys?
3. Which AI architectures perform best for variant prioritisation?
4. How can multimodal models improve rare disease diagnosis?
5. How can population diversity be incorporated into genomic AI?
6. What level of explainability is required for clinical adoption?
7. How should AI systems communicate diagnostic uncertainty?
8. Can AI-assisted diagnosis improve cost-effectiveness?
9. How can human-AI collaboration reduce diagnostic errors?
10. What governance frameworks are necessary for clinical genomic AI?

56. Future Research Directions

Future research should focus on:

- Multimodal genomic-clinical foundation models.
- AI-based phenotype discovery.
- Rare variant interpretation.
- Longitudinal patient modelling.
- Federated genomic AI.
- AI-assisted functional genomics.
- Digital phenotyping.
- AI-supported genetic counselling.
- Explainable diagnostic models.
- Real-world clinical validation.

57. Strategic Recommendations

For Researchers

- Develop multimodal datasets.
- Use diverse genomic populations.
- Establish transparent benchmarks.
- Prioritise explainability.

For Healthcare Organisations

- Integrate AI with existing clinical workflows.
- Maintain clinician oversight.
- Establish data-governance procedures.
- Monitor model performance continuously.

For Policymakers

- Develop responsible genomic-AI regulations.
- Support interoperable healthcare infrastructure.
- Protect genomic privacy.
- Encourage equitable access to genomic diagnostics.

58. Discussion

The greatest potential of AI in rare disease diagnosis lies not in replacing clinical expertise but in connecting evidence that is difficult for humans to integrate at scale.

A clinician may have access to:

- Thousands of genomic variants.
- Hundreds of clinical observations.
- Large medical records.
- Extensive biomedical literature.

AI can help organise and prioritise this evidence.

The diagnostic paradigm therefore changes from:


Human Searches → Evidence

to:

AI Integrates Evidence → Human Evaluates Evidence

59. From Genomic Data to Clinical Intelligence

The future diagnostic pathway can be conceptualised as:



This represents the transition from genomic information to clinical intelligence.

60. Conclusion

AI-assisted rare disease diagnosis represents an important convergence between artificial intelligence, genomic medicine and clinical decision support.

The integration of genomic evidence with:

- Clinical phenotypes.
- Laboratory findings.
- Medical imaging.
- Family history.
- Biomedical literature.
- Multi-omics information.

can provide a richer basis for diagnostic reasoning than any individual data source alone.


AI can particularly contribute to:

- Variant prioritisation.
- Phenotype matching.
- Gene discovery.
- Differential diagnosis.
- Evidence retrieval.
- Clinical information synthesis.

Nevertheless, substantial challenges remain. These include data quality, genomic diversity, variant uncertainty, algorithmic bias, explainability, privacy, clinical validation and regulatory governance.

The most appropriate future model is therefore human-AI collaborative diagnosis rather than autonomous AI diagnosis.

The emerging paradigm can be summarised as:



The convergence of AI and genomics could ultimately shorten diagnostic journeys and improve access to specialised rare disease expertise. Its success, however, will depend not simply on developing more powerful AI models, but on building trustworthy, explainable, diverse, clinically validated and ethically governed diagnostic ecosystems.

References

1. Bick, D., & Dimmock, D. (2011). Whole exome and whole genome sequencing. *Current Opinion in Pediatrics*, 23(6), 594–600.
2. Bamshad, M. J., Shendure, J. A., & others. (2019). The emerging landscape of genomic medicine. *Nature Reviews Genetics*.
3. Posey, J. E., O'Donnell-Luria, A. H., Bainbridge, M. N., et al. (2019). Insights into genetics, human biology and disease gleaned from family based genomic studies. *Genetics in Medicine*, 21, 798–812.
4. Wright, C. F., FitzPatrick, D. R., & Firth, H. V. (2018). Paediatric genomics: Diagnosing rare disease in children. *Nature Reviews Genetics*, 19, 253–268.
5. Boycott, K. M., Rath, A., Chong, J. X., et al. (2017). International cooperation to enable the diagnosis of all rare genetic diseases. *The American Journal of Human Genetics*, 100(5), 695–705.
6. Robinson, P. N., Kohler, S., Oellrich, A., et al. (2014). Improved exome prioritization of disease genes through cross-species phenotype comparison. *Genome Research*, 24, 340–348.
7. Köhler, S., Carmody, L., Vasilevsky, N. A., et al. (2019). Expansion of the Human Phenotype Ontology knowledge and resources. *Nucleic Acids Research*, 47, D1018–D1027.
8. Smedley, D., Jacobsen, J. O. B., Jäger, M., et al. (2015). Next-generation diagnostics and disease-gene discovery with the Exomiser. *Nature Protocols*, 10, 2004–2015.
9. Robinson, P. N., & Webber, C. (2014). Phenotype-driven gene prioritization for rare diseases. *Nature Reviews Genetics*.
10. Richards, S., Aziz, N., Bale, S., et al. (2015). Standards and guidelines for the interpretation of sequence variants. *Genetics in Medicine*, 17, 405–424.
11. Miller, D. T., Lee, K., Chung, W. K., et al. (2021). ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing. *Genetics in Medicine*, 23, 1381–1390.
12. Claussnitzer, M., Cho, J. H., Collins, R., et al. (2021). A brief history of human disease genetics and genomics. *Nature Reviews Genetics*, 22, 1–20.
13. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine*, 25, 44–56.
14. Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. *Nature Medicine*, 25, 24–29.